Sodium Bituminosulfonate Used to Treat Rosacea Modulates Generation of Inflammatory Mediators by Primary Human Neutrophils.
Schiffmann. Susanne S; Gunne. Sandra S; Henke. Marina M; Ulshöfer. Thomas T; Steinhilber. Dieter D; Sethmann. Annette A; Parnham. Michael J MJ
Key Findings
- SBDS reduces LL‑37 release from neutrophils
- SBDS lowers calcium influx, ROS, VEGF and elastase production
- SBDS inhibits the enzymes 5‑LO (IC50 ≈ 33 µg/mL) and KLK5 (IC50 ≈ 7.6 µg/mL)
- The inhibition of 5‑LO and KLK5 may disrupt the LTB4‑LL‑37‑calcium‑inflammation cascade
Practical Outcomes
- For biohackers interested in skin health, using a SBDS‑based product could help calm rosacea‑related inflammation by dampening LL‑37 and downstream inflammatory mediators. However, the effects appear localized to skin neutrophils, so systemic longevity or metabolic benefits are unlikely. Users should follow product directions and consider patch testing, as the study focused on cellular mechanisms rather than clinical dosing.
Summary
The research found that sodium bituminosulfonate (SBDS), a topical rosacea treatment, cuts down the release of the antimicrobial peptide LL‑37 and several inflammatory signals (calcium, ROS, VEGF, elastase) from human neutrophils, likely by blocking the enzymes 5‑LO and KLK5 that drive this pathway.
Abstract
Sodium bituminosulfonate is derived from naturally occurring sulphur-rich oil shale and is used for the treatment of the inflammatory skin disease rosacea. Major molecular players in the development of rosacea include the release of enzymes that process antimicrobial peptides which, together with reactive oxygen species (ROS) and vascular endothelial growth factor (VEGF), promote pro-inflammatory processes and angiogenesis. The aim of this study was to address the molecular mechanism(s) underlying the therapeutic benefit of the formulation sodium bituminosulfonate dry substance (SBDS), which is indicated for the treatment of skin inflammation, including rosacea. We investigated whether SBDS regulates the expression of cytokines, the release of the antimicrobial peptide LL-37, calcium mobilization, proteases (matrix metalloproteinase, elastase, kallikrein (KLK)5), VEGF or ROS in primary human neutrophils. In addition, activity assays with 5-lipoxygenase (5-LO) and recombinant human MMP9 and KLK5 were performed. We observed that SBDS reduces the release of the antimicrobial peptide LL-37, calcium, elastase, ROS and VEGF from neutrophils. Moreover, KLK5, the enzyme that converts cathelicidin to LL-37, and 5-LO that produces leukotriene (LT)A<sub>4</sub>, the precursor of LTB<sub>4</sub>, were both inhibited by SBDS with an IC<sub>50</sub> of 7.6 µg/mL and 33 µg/mL, respectively. Since LTB<sub>4</sub> induces LL-37 which, in turn, promotes increased intracellular calcium levels and thereby, ROS/VEGF/elastase release, SBDS possibly regulates the LTB<sub>4</sub>/LL-37/calcium - ROS/VEGF/elastase axis by inhibiting 5-LO and KLK5. Additional direct effects on other pro-inflammatory pathways such as ROS generation cannot be ruled out. In summary, SBDS reduces the generation of inflammatory mediators from human neutrophils possibly accounting for its anti-inflammatory effects in rosacea.
Study Information
pubmed
2021
2021-06-16T00:00:00.000Z
10.2147/jir.s313636